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Introduction {#sec1}
============

The mortality risk is one of the key measurements to evaluate the clinical severity of diseases. The case fatality ratio (CFR) quantifies the mortality risk of infectious disease when being infected, which is commonly calculated as a constant. However, changes in some external factors may vary the scale of CFR, e.g., pathogenic evolution, health status, changes in treatment strategies or medication ([@bib2]), the supply of healthcare and critical care resources ([@bib3]; [@bib28]), and exposure to the environmental factors ([@bib23]). In such situations, variation in CFR likely occurs. To explore changing dynamics on CFR, the instantaneous, or time-varying, CFR is of importance in understanding the patterns of the mortality risk ([@bib5]; [@bib10]; [@bib19]).

Recently, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China at the end of 2019 ([@bib4]; [@bib7]; [@bib9]; [@bib19]; [@bib21]; [@bib27]). The COVID-19 spread to over 200 foreign countries as of July 2020 ([@bib21]; [@bib29]). The World Health Organization (WHO) declared the outbreak to be a public health emergency of international concern on January 30, 2020 ([@bib16], [@bib17]). By the end of June 2020, there were over 13 million COVID-19 confirmed cases globally ([@bib16], [@bib17]). Previous studies estimated the constant fatality ratio from 0.7% to 1.3% among COVID-19 infections ([@bib13]; [@bib14]), from 1.4% to 2.6% among clinically diagnosable cases ([@bib13]; [@bib14]; [@bib20]), from 5.3% to 8.4% among reported cases ([@bib5]; [@bib6]; [@bib22]), at 14% among hospitalised cases ([@bib19]). Although Wu et al. ([@bib19]) attempted to construct the time-varying fatality ratio among hospitalised (severe) cases, their calculation was based on the crude ratio of the counts of the two terminal events including recovery and death. Estimating instantaneous CFR is essential for uncovering the temporal patterns of the COVID-19 mortality risk.

In this study, we developed a simple likelihood-based framework to estimate the instantaneous case fatality ratio of infectious diseases. We used the publicly available COVID-19 surveillance data in Canada as an example for demonstration.

Methods {#sec2}
=======

For the time interval (denoted by *g*) between being reported as case and the death (if the death occurs), we use *f*(∙) to denote the probability distribution function (PDF) of this time interval. For convenience, we denote the time interval between onset and death by *s* following the PDF of *h*(*s*), and the time interval between onset and death by *q* following the PDF of *δ*(*q*). Following the previous study ([@bib5]), the *g* is modelled as the difference of *s* minus *d*, i.e., *g* = *s* -- *q*, and we remark that *g* is not necessarily positive. Then, the PDF of *g*, i.e., *f*(*g*), is formulated as in Eqn (1).$$f{(g)} = \int h{(g + q)} \cdot \delta{(q)}\text{d}q.$$

Thus, if one case is reported at time *τ* who dies eventually, the value of *f*(*g*) is considered as the relative likelihood of death at time (*τ* + *g*).

Since each disease-related death is diagnosed as a case at the first place, each individual case is considered as a 'source' (or 'pool') of the death, i.e., subjects at mortality risk. We consider all reported cases as the 'pool' to generate deaths, and we model this candidate pool as a time-varying function denoted by *Φ*(*t*) at time *t*. Then, at time *t*, the *i*-th case, who is reported at time *τ*~*i*~, contributes *f*(*g* = *t* − *τ*~*i*~) to *Φ*(*t*). For the contribution from all reported cases, the *Φ*(*t*) is summated as in Eqn [(2)](#fd2){ref-type="disp-formula"}.$$\Phi{(t)} = \sum\limits_{i}f{(g = t - \tau_{i})}.$$

Hence, the reported case fatality ratio (rCFR), i.e., the fatality ratio of reported cases, at time *t* can be calculated by rCFR~*t*~ = *d*~*t*~/*Φ*~*t*~. Here, the *d*~*t*~ is the observed number of deaths at time *t*, and *Φ*~*t*~ is the discretised *Φ*(*t*) at time *t*.

To construct the likelihood profile, we model *d*~*t*~ as a binomial process with sizes at *Φ*~*t*~ (rounding to the closest integer) and successful probabilities at rCFR~*t*~ to be estimated. As such, by fitting to the daily number of deaths time series, *d*~*t*~, the rCFR~*t*~ can be estimated by using the maximum likelihood estimation approach. The 95% confidence intervals (95%CI) of rCFR~*t*~ are calculated by using the profile likelihood estimation framework with a cutoff threshold determined by a Chi-square quantile ([@bib1]), as well as previously adopted in ([@bib8]; [@bib15]; [@bib24]; [@bib26], [@bib28], [@bib27]).

Demonstration using COVID-19 surveillance data in Canada {#sec3}
========================================================

For demonstration, we used the publicly available COVID-19 surveillance data in Canada as an example to construct the instantaneous rCFR~*t*~ series. The daily reported number of COVID-19 cases and deaths time series were collected from the COVID-19 public surveillance platform released by the WHO, accessed via <https://covid19.who.int/region/amro/country/ca>. [Fig. 1](#fig1){ref-type="fig"}A and B shows the epidemic curve of COVID-19 cases and deaths in Canada from February to July 2020, respectively.Fig. 1The daily number of COVID-19 cases (panel A), deaths (panel B), and estimated reported case fatality ratio (rCFR, panel C) in Canada. In panel C, the squared dots are the points estimates, and the bars are the 95%CIs.Fig. 1

To set up the initial conditions of the model framework in Eqn ([@bib2]), we set *h*(*s*) as a Gamma distribution with mean (±SD) at 20 days (±10) referring to ([@bib14]; [@bib20]), and *δ*(*q*) as another Gamma distribution with mean (±SD) at 7 days (±4) referring to ([@bib5]). We remark that slight changes and similar alternative settings in the initial conditions will not affect our main results.

Results and discussion {#sec4}
======================

Since the first COVID-19 death reported on March 11, 2020, we estimated the instantaneous rCFR~*t*~ ranging from 0% to 23.8%, see [Fig. 1](#fig1){ref-type="fig"}C. The mean rCFR of COVID-19 was estimated at 6.9% (95%CI: 4.5--10.6). Our rCFR estimate is largely consistent with previous estimates, e.g., 5.3% in Wuhan, China ([@bib22]), 5.9% in Hubei province, China ([@bib6]), and from 5.3% to 8.4% in mainland China ([@bib5]).

Construction of the instantaneous CFR allows one to examine the temporal trends of mortality risk. By using the segmented logistic regression models ([@bib12]), we detected change in the temporal trends, i.e., structural break, of rCFR most likely appeared around May 3, 2020. We found a significant increasing trend in rCFR before May 3 in terms of odds ratio (OR) at 1.08 per week increase (95%CI: 1.03--1.14), but a significant decreasing trend after May 3 in terms of OR at 0.90 per week increase (95%CI: 0.87--0.93).

The data-driven CFR estimate is largely determined by the precision level of the number of COVID-19 cases and deaths. In this study, the reporting efforts in COVID-19 surveillance may largely affect the scale of cases data, whereas the COVID-19 associated deaths are unlikely to be mis-ascertained. Thus, on one hand, the under-ascertainment in COVID-19 number of cases may lead to an outcome that rCFR is larger than the real (unobservable) CFR. On the other hand, if we assume the fatality ratio ranging from 1.4% to 2.6% among clinically diagnosable COVID-19 cases as estimated in previous studies ([@bib13]; [@bib14]; [@bib20]), an average under-ascertainment rate in Canada ranging from 20.3% to 37.7% is calculated backwardly.

Linked to the change in the temporal trends of rCFR, we suspect that the decreasing trends in rCFR after May 3, 2020, might be due to the increase in the ascertainment rate in Canada during the same period. Speculatively, the increasing trends in rCFR before May 3 might be partially associated with insufficient intensive care preparedness during the early phase of the outbreak. However, further studies are warranted to explore evidence for these two speculative hypotheses. This study proposed an analytical approach to construct the instantaneous rCFR that can be adopted to further examine the associations with its potential determinants, e.g., pathogenic evolution, change in the cases ascertainment rate ([@bib11]; [@bib18]; [@bib25]), the supply of critical care resources ([@bib3]), and exposure to the environmental factors ([@bib23]).

The analytical approach proposed in this study has limitations. First, we presume the real number of disease-induced deaths and the time of each death are correctly reported. This setting is practically reasonable since mortality is considered as a serious clinical outcome, which is under more rigorous surveillance, and thus is unlikely mis-ascertained. Alternatively, an overdispersion setting in the likelihood profile may be incorporated to address the inaccurate ascertainment scenarios. Second, as a data-driven analysis, our estimates are relying on both statistical framework and consistency in the reported COVID-19 cases data. Note that the current framework requires fixed distributions of both the reporting delay, *δ*(*q*), and lag between onset and death, *h*(*s*), and temporal variation in either of them may undermine the statistical unbiasedness of the rCFR estimates. Nevertheless, our framework can be extended in a more complex context to address this issue. Last, most essentially, merely construct the instantaneous CFR is less important from the public health point of view, but we emphasize its extensive implementation, which is to identify the key determinants affecting the disease mortality risk, e.g., PM2.5 was found positively associated with the crude CFR of COVID-19 ([@bib23]).
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